Table 5 Clinical trials of CAR-Macrophages cell therapy in solid tumors (ClinicalTrials.gov)
CAR-M Product | Clinical trial identifier | Targeted antigen | Disease | Cell source | Clinical trial phase | Status | Estimated enrollment (EE) | Study objectives |
|---|---|---|---|---|---|---|---|---|
HER2 CAR- macrophages | NCT04660929 | HER2 | HER2 overexpressing solid tumors | Autologous macrophages (CT-0508) | Phase 1 | Recruiting | 48 | Study of anti-HER2 CAR- macrophages in subjects with HER2 overexpressing solid tumors. |
HER2 CAR-macrophages | NCT05007379 | HER2 | Breast cancer | N/A | Phase 1 | Recruiting | 100 | Collection of tumor samples to develop patients’ derived organoids to test the antitumor activity of newly developed CAR-macrophages. |
Glypican 3 (GPC3) CAR-macrophages | NCT04405778 | GPC3 | Solid tumors | N/A | Phase 1 | Recruiting | 18 | Study of TAK-102 in adult patients with GPC3-expressing previously treated solid tumors. |
Mesothelin CAR-macrophages | NCT05164666 | Mesothelin | Advanced or metastatic solid tumors | Autologous white blood cells | Phase 1 | Recruiting | 21 | Study of TAK-103 in adult patients with mesothelin-expressing advanced or metastatic solid tumors. |